1. Management of patients with high-risk and advanced prostate cancer in the Middle East: resource-stratified consensus recommendations.
- Author
-
Mukherji D, Youssef B, Dagher C, El-Hajj A, Nasr R, Geara F, Rabah D, Al Dousari S, Said R, Ashou R, Wazzan W, Jabbour M, Farha G, Al Hamdani N, Al Hallaq Y, Ghazal H, Dbouk H, Bachir B, El Khoury C, Sakr G, Hussain HK, Sayyid K, Ibrahim K, Haidar M, Zouain N, Bitar N, Alameh W, Abbas F, Faddoul S, Nemer E, Assaf G, Farhat F, Bulbul M, Temraz S, Shamseddine A, Gillessen S, Omlin A, and Khauli R
- Subjects
- Abiraterone Acetate therapeutic use, Antineoplastic Agents therapeutic use, Benzamides, Biopsy, Large-Core Needle, Bone Neoplasms secondary, Bone Neoplasms therapy, Docetaxel therapeutic use, Endosonography, Humans, Iraq, Kallikreins metabolism, Kuwait, Lebanon, Lymph Node Excision, Magnetic Resonance Imaging, Male, Margins of Excision, Middle East, Neoplasm Metastasis, Nitriles, Phenylthiohydantoin analogs & derivatives, Phenylthiohydantoin therapeutic use, Positron-Emission Tomography, Prostate-Specific Antigen metabolism, Prostatic Neoplasms diagnosis, Prostatic Neoplasms epidemiology, Prostatic Neoplasms pathology, Prostatic Neoplasms, Castration-Resistant diagnosis, Prostatic Neoplasms, Castration-Resistant epidemiology, Prostatic Neoplasms, Castration-Resistant pathology, Prostatic Neoplasms, Castration-Resistant therapy, Risk, Salvage Therapy, Saudi Arabia, Syria, Androgen Antagonists therapeutic use, Antineoplastic Agents, Hormonal therapeutic use, Health Resources, Health Services Accessibility, Prostatectomy, Prostatic Neoplasms therapy, Radiotherapy, Adjuvant
- Abstract
Purpose: Prostate cancer care in the Middle East is highly variable and access to specialist multidisciplinary management is limited. Academic tertiary referral centers offer cutting-edge diagnosis and treatment; however, in many parts of the region, patients are managed by non-specialists with limited resources. Due to many factors including lack of awareness and lack of prostate-specific antigen (PSA) screening, a high percentage of men present with locally advanced and metastatic prostate cancer at diagnosis. The aim of these recommendations is to assist clinicians in managing patients with different levels of access to diagnostic and treatment modalities., Methods: The first Advanced Prostate Cancer Consensus Conference (APCCC) satellite meeting for the Middle East was held in Beirut, Lebanon, November 2017. During this meeting a consortium of urologists, medical oncologists, radiation oncologist and imaging specialists practicing in Lebanon, Syria, Iraq, Kuwait and Saudi Arabia voted on a selection of consensus questions. An additional workshop to formulate resource-stratified consensus recommendations was held in March 2019., Results: Variations in practice based on available resources have been proposed to form resource-stratified recommendations for imaging at diagnosis, initial management of localized prostate cancer requiring therapy, treatment of castration-sensitive/naïve advanced prostate cancer and treatment of castration-resistant prostate cancer., Conclusion: This is the first regional consensus on prostate cancer management from the Middle East. The following recommendations will be useful to urologists and oncologists practicing in all areas with limited access to specialist multi-disciplinary teams, diagnostic modalities and treatment resources.
- Published
- 2020
- Full Text
- View/download PDF